NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/29/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization85.46 mln
Float66.69 mln
Earnings Date07/30/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.18
Caution advised
1-Year Forecast
5.21
Transformational upside
Relative Strength
6
/ 100
Severely lagging
Debt / Equity
0.02
Debt-free
ROE
-86.62
Deeply negative
Business Description
Cardiff Oncology is a San Diego-based biotechnology company focused on developing new cancer treatments. Its primary asset is Onvansertib, an oral drug targeting a protein called polo-like kinase 1, which is being studied in patients with colorectal cancer carrying specific genetic mutations known as RAS or KRAS. The company is running several clinical trials across multiple cancer types, including pancreatic cancer, lung cancer, breast cancer, and leukemia. Founded in 1999 and formerly known as Trovagene, Cardiff Oncology continues to advance its pipeline through partnerships with researchers and multi-center study programs.
